BIO: Caribou tries to 'go where the puck is going' by taking on cell therapy rivals on home ice

Caribou Biosciences doesn't want to follow the leader as its cell therapy rival backs off to focus on relapsed patients with lymphoma. Instead, CEO Rachel Haurwitz, Ph.D., says the CRISPR-focused company is looking a few plays ahead.